Xenetic Biosciences reports Q3 2022 net loss of $0.8M; cash of $13.8M

Xenetic Biosciences, Inc.

2022-Q3 EPS reported -$0.36 revenue$1,219,953

Net loss for Q3 2022 was approximately $0.8 million.
R&D expenses fell 48.9% YoY to $0.4 million, reflecting shift from XCART to DNase platform.
G&A expenses decreased 8.7% to $863,000.
Cash and cash equivalents were $13.8 million at quarter-end; expected to fund operations and pipeline development.
DNase oncology platform advancing toward first-in-human study for pancreatic carcinoma.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Xenetic Biosciences, Inc. reported the three months ended September 30, 2022 results: net income approximately $0.8 million.

Period: the three months ended September 30, 2022
Net income: approximately $0.8 million
Result: reported results

Exact text from the filing

Net loss for the quarter ended September 30, 2022 was approximately $0.8 million.

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Xenetic Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001683168-22-007476

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.